Brokers Issue Forecasts for MNPR FY2026 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Stock analysts at Brookline Capital Markets boosted their FY2026 earnings estimates for shares of Monopar Therapeutics in a report released on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings of ($2.61) per share for the year, up from their previous forecast of ($2.70). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.96) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($0.80) EPS.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.72).

A number of other equities analysts also recently weighed in on the company. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research note on Thursday, July 23rd. Barclays reaffirmed an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Finally, Morgan Stanley lifted their target price on Monopar Therapeutics from $130.00 to $133.00 and gave the stock an “overweight” rating in a research note on Monday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Monopar Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.12.

Check Out Our Latest Report on MNPR

Monopar Therapeutics Trading Down 0.0%

Shares of NASDAQ:MNPR opened at $71.97 on Tuesday. Monopar Therapeutics has a 52-week low of $50.07 and a 52-week high of $124.82. The company has a 50-day simple moving average of $81.68 and a 200 day simple moving average of $77.43.

Insider Activity at Monopar Therapeutics

In other news, CEO Chandler Robinson sold 29,056 shares of the stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the transaction, the chief executive officer directly owned 99,267 shares of the company’s stock, valued at $8,735,496. This represents a 22.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 4,090 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the transaction, the director directly owned 7,396 shares in the company, valued at $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,920 shares of company stock valued at $4,527,913 in the last ninety days. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its position in Monopar Therapeutics by 443.8% during the third quarter. Goldman Sachs Group Inc. now owns 87,877 shares of the company’s stock worth $7,001,000 after acquiring an additional 71,716 shares during the last quarter. State Street Corp boosted its holdings in shares of Monopar Therapeutics by 24.1% during the third quarter. State Street Corp now owns 229,771 shares of the company’s stock worth $18,306,000 after acquiring an additional 44,669 shares during the period. Meeder Asset Management Inc. boosted its holdings in shares of Monopar Therapeutics by 18.9% during the third quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company’s stock worth $132,000 after acquiring an additional 262 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Monopar Therapeutics in the second quarter valued at approximately $7,124,000. Finally, Bank of America Corp DE grew its position in shares of Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after purchasing an additional 53,336 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

See Also

Earnings History and Estimates for Monopar Therapeutics (NASDAQ:MNPR)

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.